Melbourne Clinical Trials

Hepatitis B Treatment Study

This study is looking at a potential new medication for chronic hepatitis B called Selgantolimod.

10 nights
1 follow up call visits

The purpose of this study is to understand the interaction between this medication and two already approved medications. These approved medications, called Omeprazole and Famotidine, decrease stomach acid production and are commonly used to treat reflux disease. For the initial stage of research into this medication, we require healthy participants with no medical conditions. This is so we can look at how the body metabolises the medications when taken together.

Eligibility

Biological Sex Healthy male and females
Age 18 - 45 years old
BMI 19 - 30 kg/m²
Medication Not taking any (contraception and vitamins are permitted)
Medical History Nothing significant
Smoking History Non-smokers or occasional smokers of no more than 5 cigarettes per week